MassDevice.com +5 | The top 5 medtech stories for April 25, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Questions surface about Palmaz Scientific’s fundraising Palmaz Scientific, which filed for Chapter 11 bankruptcy protection last month, is reportedly embroiled in a dispute with Jefferies & Co. over its claim that the prominent investment bank was the placement agent for a funding round in 2012 and 2013. Co-founded by coronary stent pioneer Dr. Julio Palmaz in 2008, the San Antonio, Texas-based company tapped Jefferies for a $7.5 million round in 2010, according to the San Antonio Express-News. But despite the fact that the Wall Street firm severed its ties with Palmaz Scientific in 2011, according to the newspaper, the medical device company continued to list Jefferies as the placement agent for another 2 years in marketing materials. Read more 4. FDA grants IDE to NovoCure for phase II Optune trial NovoCure said today that Radiation Therapy Oncology Group Foundation won FDA investigational device exemption to conduct a Phase II pilot test of NovoCure’s Optune in conjunction with bevacizumab to treat bevacizumab-refractory recurrent glioblastoma. The Optune is a m...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news